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Rheumatoid arthritis (RA) is a chronic inflammatory disease in which pro-inflammatory
cytokines, including tumor necrosis factor (TNF)-α, play a crucial role. The chronic inflam-
mation, combined with reduced physical activity, leads to muscle wasting whereas fat mass
would be maintained; the resulting abnormal metabolic state is described as rheumatoid
cachexia. Since the loss of muscle volume would be compensated by the increased fat
mass, body mass index (BMI) is reported not to reflect the nutritional status in RA patients.
The implication of rheumatoid cachexia for cardiovascular risk and clinical prognosis is
not clearly understood, however, adequate control of disease activity in combination with
appropriate physical exercise could be the most important strategy to control rheumatoid
cachexia and related metabolic problems.
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INTRODUCTION
Recent advances in the management of rheumatoid arthritis (RA)
have reduced the frequency of so-called “cachexia” in RA patients.
In such “classic” cachexia, patients often look emaciated, under a
malignant or chronic inflammatory condition with appetite loss
and protein degradation. However, in RA, persistent inflammation
may induce muscular wasting without thinning; the muscle loss
in RA would be associated with normal or even obese appearance.
The condition has been named “rheumatoid cachexia.” Although
its impact on morbidity and mortality has been suggested, the sig-
nificance of rheumatoid cachexia is not fully understood in part
because of the lack of specific symptoms.
The present article reviews the current concept of rheumatoid
cachexia, including the confusion regarding its clinical definition,
and highlights the potential importance of physical exercise and
nutritional assessment in the therapeutic strategy against RA.
DEFINITION OF CACHEXIA AND RELATED CONDITIONS
CACHEXIA (IN CLASSIC MEANING)
Cachexia is manifested by unintended severe weight loss and mus-
cle wasting, and can be defined as “a multifactorial syndrome
characterized by severe weight, fat and muscle loss, and increased
protein catabolism due to underlying disease(s)” (1, 2). The term
“cachexia” originates from the ancient Greek for “bad condition,”
and often occurs in patients with advanced malignancy (cancer
cachexia); chronic heart failure (cardiac cachexia); chronic renal
failure; chronic obstructive pulmonary disease (COPD); acquired
immunodeficiency syndrome (AIDS); and many other chronic
diseases, including advanced RA.
Clinically, cachexia can be detected by assessment of body
composition (i.e., measurement of muscle mass and fat mass)
generally using bioimpedance analysis (BIA) or dual-energy X-ray
absorptiometry (DEXA). Muscle mass can be measured as fat-free
mass (FFM) by BIA, or lean body mass (LBM) by DEXA; values
reflect the estimated mass of skeletal muscle and its metabolic
activity.
Since cachexia is known to be a major cause of increased
mortality, “early and effective interventions” are needed to pre-
vent the development of fatal metabolic abnormalities (1). To
this end, efforts have been made to develop and share a con-
sensus on the clinical definition of cachexia, including diagnostic
criteria. In 2005, the Special Interest Group (SIG) on cachexia–
anorexia in chronic wasting diseases was created in the Euro-
pean Society for Clinical Nutrition and Metabolism (ESPEN) (2).
The SIG developed a clinical definition of cachexia (Table 1),
and to prevent delayed diagnosis and intervention, introduced
the term “pre-cachexia.” Pre-cachexia was defined as the simul-
taneous presence of the following four features; an underlying
chronic disease; unintentional body weight (BW) loss (≤5%) [cf:
(≥) in cachexia] during the last 6 months; chronic or recurrent
systemic inflammation; and anorexia or symptoms of appetite
loss (2).
Both cachexia and pre-cachexia are frequently associated with
inflammation; an imbalance between pro-inflammatory (TNF-α,
Interleukin (IL)-6, and IL-1) and anti-inflammatory (e.g., IL-4, IL-
12, IL-15) cytokines is considered to contribute to the pathogenesis
(2, 3) (Table 1).
SARCOPENIA
Sarcopenia is defined as “a syndrome characterized by progressive
and generalized loss of skeletal muscle mass and strength with a
risk of adverse outcomes such as physical disability, poor qual-
ity of life, and death” (3). Primary sarcopenia is usually due to
aging, while secondary sarcopenia occurs due to chronic illness,
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Table 1 | Clinical criteria for cachexia, rheumatoid cachexia, and sarcopenia.
Criteria Classic Cachexia Rheumatoid Cachexia Sarcopenia
Reference ESPEN-SIGs (2) Engvall (20) Elkan (19) ESPEN-SIGs (2) EWGSOP (3)
Concept Loss of body weight; loss
of both lean and fat mass;
loss of skeletal muscle
mass
Decreased FFM and increased fat mass Loss of skeletal muscle mass and strength
Underlying
chronic disease
+ Rheumatoid Arthritis ±
Body
weight/BMI
[*] Unintentional weight
loss (≥5%) during the last
12 months, or BMI
<20 kg/m2
→ or ↑
Muscle
strength
[1] Decreased muscle
strength
[1] Decreased muscle
strength, e.g., low handgrip
strength (<30 kg in men, or
<20 kg in women)
Fatigue [2] Fatigue
Appetite
(continued)
[3] Anorexia or
anorexia-related symptoms
Body
composition
[4] Low FFM (lowest 10%) FFMI <10th
percentile and
FMI >25th
percentile
FFMI <25th
percentile and FMI
>50th percentile
[*] Low muscle mass; e.g.,
≥2 SD below the mean in
young adults of the same
sex and ethnic background
[*] Low muscle mass; e.g.,
≥2 SD below the mean in
young adults
Role of
cytokines
[5] Evidence of cytokine
excess: (1) CRP
>0.5 mg/dL or IL-6 >4.0
pg/ml, (2) Hb <12 g/dl, (3)
Alb <3.2 g/dL
Dominance of inflammatory cytokines
(in particular TNFα and IL-6) due to
inflammatory arthritis
Fat mass ↓ → or ↑ → (or ↑ in sarcopenic obesity)
Physical
performance
[1] Low gait speed
(≤0.8 m/s in the 4-m
walking test);
[2] reduced performance
test (used fro the CGA)
[2] E.g., Low usual gait speed
(≤0.8 m/s in the 4-m walking
test) and/or
[2] Low physical performance,
SPPB ≤8
Diagnostic
criteria
Defined as cachexia if [*]
plus ≥3 among [1] to [5]
are fulfilled
No consensus on the cut-off values Defined as sarcopenia if [*]
plus [1] or [2] are fulfilled
Defined as sarcopenia if [*]
plus [1] or either of [2] are
fulfilled
[*] indicates necessary condition for the diagnosis of “classic condition”.
[1–5] indicates other conditions used for the diagnosis. (as described in “Diagnostic Criteria” in the Table).
Modified from Muscaritoli et al. (2). EWGSOP, European Working Group on Sarcopenia in Older People: FFM, fat-free mass; FFMI, fat-free mass index; CGA,
Comprehensive Geriatric Assessment; SPPB, short physical performance battery, Hb, hemoglobin; Alb, albumin; SD, standard deviation.
immobility, and/or malnutrition. Although sarcopenia is generally
an age-related condition, it can develop at a younger age, similar to
other typically age-related conditions such as dementia and osteo-
porosis (3). The European Working Group on Sarcopenia in Older
People (EWGSOP) developed a clinical definition, and consen-
sus diagnostic criteria for sarcopenia (Table 1). According to this
definition, most cachectic patients are sarcopenic, but sarcopenic
patients are not necessarily cachectic (3).
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In sarcopenia, the decreased muscle mass may be associated
with normal, or even increased fat mass, a condition termed “sar-
copenic obesity.” It has been reported that fat infiltration into
muscle would lower muscle quality (3).
RHEUMATOID CACHEXIA
Rheumatoid arthritis is an autoimmune disease that affects multi-
ple synovial joints, and is associated with multiple extra-articular
manifestations. Synovial fibroblasts and macrophages, activated
by an unknown trigger, proliferate and produce a plethora of
pro-inflammatory cytokines and catabolic proteases that would
degrade bone and cartilage.
Due to the chronic inflammation, RA patients often exert
abnormal metabolism, including insulin resistance (4, 5). Fur-
ther, patients with refractory RA or in advanced stage of RA have
been recognized to be at risk of cachexia. To this concern, for
example, apparent BW loss (≥5% in past 12 months) was in 1.0%,
whereas anorexia was shown in 5.8 (when assessed with visual ana-
log scale) to 10.7% (when assessed with the functional assessment
of anorexia/cachexia therapy), in RA patients; overall, it has been
estimated that patients with “classic” cachexia (Table 1) would be
approximately 1.0% in RA patients (6). In addition, to support
the inflammation-induced cachectic condition, an animal model
of RA had decreased daily food intake (anorexia) and BW loss,
accompanied with muscle wasting (7). Nevertheless, RA patients
do not necessarily lose BW and often show normal range of BMI;
thus may not fit into the diagnostic criteria of “cachexia” (as indi-
cated in Table 1). Instead, a unique abnormal metabolic state, i.e.,
rheumatoid cachexia, has been proposed.
Specifically, in early studies, Roubenoff et al. documented
decreased body cell mass (BCM) and increased resting energy
expenditure (REE) in patients with RA, suggesting involvement of
cytokine-driven hyper-metabolism (8, 9). The authors concluded
that “cytokine production in RA is associated with altered energy
metabolism and intake, despite a theoretically adequate diet,” and
defined the condition of reduced BCM without obvious fat loss as
“rheumatoid cachexia” (8, 10). Thus, long-standing inflammation
in RA leads to a state of hyper-metabolism resulting in muscle
wasting (11).
A number of studies followed to assess the clinical implications
of altered body composition in RA [Table S1 in Supplementary
Material; earlier studies are summarized in a review by Summers
et al. (12)]. Most reports documented that muscle mass in RA
patients was decreased, whereas the fat mass remained normal,
or was increased. REE was normal or increased, with some stud-
ies showing a correlation between REE and disease activity (11,
13, 14). On the other hand, total energy expenditure (TEE) was
reported to be lower than healthy controls (15), that is attributed
to a reduced physical activity (16, 17).
Overall, the combined effect (i.e., loss of muscle mass and
normal fat deposition) would keep BW within a normal range
(18). This condition can be defined as rheumatoid cachexia, or
rheumatoid cachectic obesity (8, 10, 13), which is consistent with
reports that BMI is not appropriate to detect rheumatoid cachexia
(19, 21). In addition, the widely used mini nutritional assess-
ment (MNA) was not a powerful tool for detection of rheumatoid
cachexia (19, 21).
To date, there remain no consensus clinical criteria for the diag-
nosis of rheumatoid cachexia. Van Bokhorst-de van der Schueren
et al. (6) assessed the feasibility of using the ESPEN SIG defini-
tion of cachexia in a sample of 103 RA patients, and concluded
that the definition was inappropriate, since reductions in BW and
appetite are not apparent in RA. Engvall et al. (20) and Elkan (22)
defined rheumatoid cachexia using different criteria (Table 1),
and estimated the frequency of rheumatoid cachexia as 38%, or
18% of women and 21% of men, respectively. Effort is there-
fore needed to establish the diagnostic criteria for rheumatoid
cachexia (18).
PATHOGENESIS OF RHEUMATOID CACHEXIA
A variety of factors are involved in the pathogenesis of clas-
sic cachexia, including suppression of the growth hormone
(GH)/insulin-like growth factor (IGF) system; testosterone defi-
ciency; and an excess of myostatin and glucocorticoids (16).
In rheumatoid cachexia, relative excess of pro-inflammatory
cytokines is considered to be the central feature (9). Pro-
inflammatory cytokines including TNFα, IL-1β, IL-6, and IFN-γ,
the key players of synovitis and extra-articular manifestations, may
activate the nuclear factor κB and lead to an increase in muscle
proteolysis via the ubiquitin-proteasome pathway (16). Overex-
pression of IL-1β would also induce anorexia and exacerbate
muscle loss (9). Further, use of glucocorticoid as a pharmaco-
logical treatment against symptoms of RA might aggravate the
rheumatoid cachexia. More specifically, glucocorticoids have been
shown to induce muscle atrophy (steroid myopathy) through acti-
vation of the transcription factor FOXO or repression of mTOR
signaling, leading to protein catabolism (23).
The GH-IGF axis may also be an important contributor,
although controversy exists (24). In an animal model of chronic
inflammatory arthritis, Ibanez de Caceres et al. reported a decrease
in BW and reduced levels of circulating IGF-1; administration of
recombinant GH was associated with increased BW gain with-
out an increase in food intake, and increased levels of IGF-1
(25). On the other hand, in the model, arthritis was also asso-
ciated with increased expression of the cyclooxygenase (COX)-
2 gene; and administration of non-steroidal anti-inflammatory
drugs (NSAIDS) reversed the COX’s inhibitory effect of arthritis
on BW, increased liver IGF-1 levels, and enhanced the expression
of ubiquitin-ligating enzymes. The authors suggested that COX-
2 expression was responsible for the arthritis-induced cachexia,
through modification of the GH-IGF axis and the ubiquitin-
proteasome pathways (25). The use of recombinant GH in
cachectic humans has been also approved for use in patients
with AIDS (26); however, its efficacy in patients with RA is
unclear.
THERAPEUTIC STRATEGY AGAINST RHEUMATOID CACHEXIA
The consequences of rheumatoid cachexia go beyond muscle
wasting and fat deposition; while any impact on cardiovascular
risk remains controversial (18), it is suggested that rheumatoid
cachexia exacerbates RA-associated disability and morbidity (17,
27), probably leading to sarcopenia. The muscle volume of RA
patients is reported to correlate with RA activity, not with dietary
intake (14, 17). Further, even in RA patients with a high dietary
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intake of saturated fat, there was no correlation between fatty acid
intake and rheumatoid cachexia (22). The most important strat-
egy against metabolic abnormalities in RA may be the appropriate
suppression of disease activity, for example, using anti-cytokine
therapy and physical exercise (28).
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Rheumatoid arthritis patients typically start anti-rheumatic ther-
apy using conventional disease-modifying anti-rheumatic drugs
(DMARDs), which may include methotrexate (MTX) as an anchor
drug, and sulfasalazine (SSZ). These agents are effective in the sup-
pression of disease activity,particularly when used in combination.
The use of DMARDs in early RA is also reported to improve insulin
resistance and dyslipidemia (5, 29, 30); this is likely due to their
disease-modifying effects, rather than a direct effect on metabo-
lism, since neither MTX nor azathioprine, when used alongside
NSAIDs, was shown to affect energy metabolism in RA patients
(9). Indeed, insulin resistance in RA patients was shown to be
higher than that observed in patients with systemic lupus erythe-
matosus, and was correlated with serum levels of IL-6, TNFα, and
C-reactive protein (CRP) (30, 31). Perhaps surprisingly, use of pre-
donisolone in RA patients had no correlation with BCM (Table S1
in Supplementary Material) (9).
ANTI-CYTOKINE THERAPIES
Over the last decade, data have accumulated regarding the long-
term use of anti-TNF agents in RA patients. While solid evidence
exists for their anti-arthritic efficacy, few reports indicate whether
anti-TNF agents could improve rheumatoid cachexia.
Marcora et al. (32) analyzed change in body composition in
26 RA patients after 24 weeks treatment using etanercept (ETN)
or MTX, and failed to find significant benefit of ETN compared
with MTX. However, in a subgroup analysis of patients who
gained BW during treatment, the ETN-treated patients gained
a greater proportion of FFM (in the composition of the BW
gained) than the MTX-treated group. Similarly, Elkan et al. (21)
found no correlation between use of anti-TNF agents and body
composition.
After a longer period of observation (1 year), Chen et al.
(33) found that twice weekly administration of ETN was associ-
ated with increased BW, and increased serum levels of glucose-
dependent insulinotropic polypeptide (GIP), leptin, and ghre-
lin compared with treatment with DMARDs. Further, a recent
prospective study (34) involving a 2-year period of TNFα inhibi-
tion, demonstrated an increase in BW, BMI, total fat mass, and
fat in the android (truncal) region; visceral fat also increased,
without any change in serum leptin and adiponectin levels. The
authors concluded that long-term TNF inhibition was associated
with increased fat mass, with a shift to the android-visceral region,
raising questions regarding the influence of TNF inhibition on car-
diovascular risk. This association is surprising, given that anti-TNF
therapy is reported to improve insulin resistance in RA patients
(30, 35–38).
IL-6 is another important pathogenic cytokine in both clas-
sic and rheumatoid cachexia. Serum IL-6 levels in RA patients are
higher than those of healthy individuals, and are reported to corre-
late with a high REE (11, 14). However, it remains unclear whether
IL-6 levels correlate with muscle mass and/or visceral fat mass in
RA (11). Further studies are needed to clarify the involvement of
IL-6 in muscle degradation, and the potential effect of the anti-
rheumatic agent tocilizmab, a widely used monoclonal antibody
against the IL-6 receptor, in rheumatoid cachexia.
RESISTANCE TRAINING AND ENDURANCE TRAINING
Summers et al. suggested that alongside anti-cytokine therapy,
adjunctive anabolic therapy, such as high-intensity progressive
resistance training (PRT) or nitrogen supplementation would be
necessary to treat rheumatoid cachexia (12).
Accumulating evidence supports the significant clinical ben-
efit of resistance training in patients with RA [reviewed in Ref.
(28)]. Regular training not only increased muscle strength but also
improved disease activity, pain, Health Assessment Questionnaire
(HAQ) scores, and walking speed in RA patients (28, 39–45). For
example, Marcola (44) and Lemmey et al. (45) reported that PRT
for a period of 12 and 24 weeks, respectively, increased muscle mass
while reducing fat mass. Lemmey et al. also reported improve-
ments in physical performance, while levels of muscle IGF-1 and
IGF-binding protein (IGFBP)-3 in muscle increased (45).
Besides the resistance training, endurance training (ET) is also
important to improve insulin sensitivity and body composition
(46). In a report by Mikkelsen et al. (47), it was revealed that
life-long endurance exercise was associated with lower levels of
circulating CRP and IL-6 levels, and also with a greater muscle
area compared to untrained controls, indicating potential anti-
inflammatory effect of ET. In fact, the combination of resistance
training and ET has been demonstrated to increase lean body mass
and to decrease body fat in RA patients (48, 49). These findings
suggest the therapeutic potential of these physical therapies in RA
and other chronic inflammatory conditions.
OTHER APPROACHES
α-Melanocyte-stimulating hormone (α-MSH) is a proopiome-
lanocortin (POMC)-derived neuropeptide that exerts anorexi-
genic and anti-inflammatory properties (50). Recently, Gómez-
SanMiguel et al. (7) reported that systemic administration of
α-MSH to arthritis model mice resulted in improved food intake
and higher BW gain with decreased arthritis signs. The authors
found that increase in hypothalamic expressions of COX-2, IL-
1β, POMC, and Agouti-related protein (a stimulator of appetite)
mRNA were prevented by α-MSH administration in the arthritic
mice.α-MSH treatment also decreased expressions of E3 ubiquitin
ligases, which are markers of muscular atrophy. Thus peripheral
α-MSH treatment is suggested to be an anti-cachectic strategy in
arthritis.
Other approaches such as anabolic steroids or recombinant
human GH have been proposed, however, there is no evidence to
show their safety and efficacy (28).
CONCLUDING REMARKS
Recent progress in anti-rheumatic therapies has made “classic”
cachexia less frequent among RA patients. Nevertheless, a differ-
ent form of abnormal metabolism, “rheumatoid cachexia,” has
emerged, that may promote comorbid risks and deterioration in
physical activity in RA patients (Figure 1).
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FIGURE 1 | Pathogenesis of rheumatoid cachexia (a hypothesis). NSAIDs, non-steroidal anti-inflammatory drugs, COX, cyclooxygenase; DMARDs,
disease-modifying anti-rheumatic drugs.
To overcome the muscle loss and fat deposit in RA, it will
be essential to first establish a consensus regarding definition
of this disorder. Possible overlap with sarcopenia should be also
noted. Further, tight control of disease activity, along with phys-
ical exercise and appropriate nutritional management, should be
recommended to improve energy expenditure and reduce insulin
resistance in RA patients.
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Table S1 | Reported changes of indices of body composition in RA patients.
References: (6, 8, 10, 15, 16, 18, 20, 24, 43–50). Disease Activity Score-28 (51)
of the tested patients were 2.6–6.39 and the Health Assessment Questionnaire
(52) score was around 0.22–1.95. BCM, body cell mass; FFM, fat-free mass;
LBM, lean body mass; AMA, arm muscle area, TEE: total energy expenditure,
REE: resting energy expenditure. Biologics: TNF, TNFα inhibitors; IL-6, IL-6
receptor antagonist; CD20, CD20 inhibitor; ↑, increased; ↓, decreased;→, no
change compared with the control group, respectively. *Values shown are at
the patient’s first visit (baseline).
REFERENCES
1. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al.
Cachexia: a new definition. Clin Nutr (2008) 27:793–9. doi:10.1016/j.clnu.2008.
06.013
2. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Con-
sensus definition of sarcopenia, cachexia and pre-cachexia: joint document
elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic
wasting diseases” and “nutrition in geriatrics”. Clin Nutr (2010) 29:154–9.
doi:10.1016/j.clnu.2009.12.004
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.
Sarcopenia: European consensus on definition and diagnosis: report of the
European Working Group on Sarcopenia in Older People. Age Ageing (2010)
39:412–23. doi:10.1093/ageing/afq034
4. Svenson KL, Pollare T, Lithell H, Hallgren R. Impaired glucose handling in active
rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism
(1988) 37:125–30. doi:10.1016/S0026-0495(98)90005-1
5. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al.
Inflammation-associated insulin resistance: differential effects in rheumatoid
arthritis and systemic lupus erythematosus define potential mechanisms. Arthri-
tis Rheum (2008) 58:2105–12. doi:10.1002/art.23600
6. van Bokhorst-de van der Schueren MA, Konijn NP, Bultink IE, Lems WF, Earth-
man CP. Relevance of the new pre-cachexia and cachexia definitions for patients
with rheumatoid arthritis. Clin Nutr (2012) 31:1008–10. doi:10.1016/j.clnu.
2012.05.012
7. Gómez-SanMiguel AB, Martin AI, Nieto-Bona MP, Fernandez-Galaz C, Lopez-
Menduina M, Villanua MA, et al. Systemic alpha-melanocyte-stimulating hor-
mone administration decreases arthritis-induced anorexia and muscle wast-
ing. Am J Physiol Regul Integr Comp Physiol (2013) 304:R877–86. doi:10.1152/
ajpregu.00447.2012
8. Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB. Rheuma-
toid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible
association with tumor necrosis factor. J Rheumatol (1992) 19:1505–10.
9. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-
Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism
accompanying reduced body cell mass in chronic inflammation. J Clin Invest
(1994) 93:2379–86. doi:10.1172/JCI117244
10. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol (2002)
85:89–99. doi:10.1016/S0167-5273(02)00237-1
11. Arshad A, Rashid R, Benjamin K. The effect of disease activity on fat-free mass
and resting energy expenditure in patients with rheumatoid arthritis versus
noninflammatory arthropathies/soft tissue rheumatism. Mod Rheumatol (2007)
17:470–5. doi:10.3109/s10165-007-0628-1
www.frontiersin.org November 2014 | Volume 1 | Article 20 | 5
Masuko Rheumatoid cachexia revisited
12. Summers G, Deighton C, Rennie M, Booth A. Rheumatoid cachexia: a
clinical perspective. Rheumatology (Oxford) (2008) 47:1124–31. doi:10.1093/
rheumatology/ken146
13. Roubenoff R, Walsmith J, Lundgren N, Snydman L, Dolnikowski GJ, Roberts S.
Low physical activity reduces total energy expenditure in women with rheuma-
toid arthritis: implications for dietary intake recommendations. Am J Clin Nutr
(2002) 76:774–9.
14. Binymin K, Herrick A, Carlson G, Hopkins S. The effect of disease activity on
body composition and resting energy expenditure in patients with rheumatoid
arthritis. J Inflamm Res (2011) 4:61–6. doi:10.2147/JIR.S16508
15. Henchoz Y, Bastardot F, Guessous I, Theler JM, Dudler J, Vollenweider P,
et al. Physical activity and energy expenditure in rheumatoid arthritis patients
and matched controls. Rheumatology (Oxford) (2012) 51:1500–7. doi:10.1093/
rheumatology/kes067
16. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical
relevance. Am J Clin Nutr (2006) 83:735–43.
17. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mech-
anisms and interventions. Rheumatology (Oxford) (2004) 43:1219–23. doi:10.
1093/rheumatology/keh321
18. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheuma-
toid cachexia and cardiovascular disease. Nat Rev Rheumatol (2010) 6:445–51.
doi:10.1038/nrrheum.2010.105
19. Elkan A, Engvall I, Tengstrand B, Cederholm T, Hafstrom I. Malnutrition in
women with rheumatoid arthritis is not revealed by clinical anthropomet-
rical measurements or nutritional evaluation tools. Eur J Clin Nutr (2008)
62:1239–47. doi:10.1038/sj.ejcn.1602845
20. Engvall I, Elkan A, Tengstrand B, Cederholm T, Brismar K, Hafstrom I. Cachexia
in rheumatoid arthritis is associated with inflammatory activity, physical disabil-
ity, and low bioavailable insulin-like growth factor. Scand J Rheumatol (2008)
37:1–8. doi:10.1080/03009740802055984
21. Elkan AC, Engvall IL, Cederholm T, Hafstrom I. Rheumatoid cachexia,
central obesity and malnutrition in patients with low-active rheumatoid
arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body
composition techniques. Eur J Nutr (2009) 48:315–22. doi:10.1007/s00394-009-
0017-y
22. Elkan AC, Hakansson N, Frostegard J, Cederholm T, Hafstrom I. Rheumatoid
cachexia is associated with dyslipidemia and low levels of atheroprotective nat-
ural antibodies against phosphorylcholine but not with dietary fat in patients
with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther (2009)
11:R37. doi:10.1186/ar2643
23. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced
myopathy. J Endocrinol (2008) 197:1–10. doi:10.1677/JOE-07-0606
24. Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, et al.
Cachexia in rheumatoid arthritis is not explained by decreased growth hormone
secretion. Arthritis Rheum (2002) 46:2574–7. doi:10.1002/art.10714
25. Ibanez De Caceres I, Villanua MA, Soto L, Martin AI, Lopez-Calderon A.
IGF-I and IGF-I-binding proteins in rats with adjuvant-induced arthritis
given recombinant human growth hormone. J Endocrinol (2000) 165:537–44.
doi:10.1677/joe.0.1650537
26. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and
anabolic steroids in cachexia and wasting. Am J Clin Nutr (2010) 91:1143S–7S.
doi:10.3945/ajcn.2010.28608E
27. Walsmith J, Abad L, Kehayias J, Roubenoff R. Tumor necrosis factor-alpha pro-
duction is associated with less body cell mass in women with rheumatoid arthri-
tis. J Rheumatol (2004) 31:23–9.
28. Lemmey A. Resistance training for patients with rheumatoid arthritis: effects
on disability, rheumatoid cachexia, and osteoporosis; and recommendations for
prescription. In: Lemmey DA, editor. Rheumatoid Arthritis – Treatment. Rijeka,
Croatia: InTech (2012). p. 287–310.
29. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary
intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a
pilot study. Arthritis Res (2002) 4:R12. doi:10.1186/ar428
30. Ferraz-Amaro I, Gonzalez-Juanatey C, Lopez-Mejias R, Riancho-Zarrabeitia
L, Gonzalez-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators
Inflamm (2013) 2013:710928. doi:10.1155/2013/710928
31. Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S,Wallander MA. Rheumatoid
arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol
(2009) 38:173–7. doi:10.1080/03009740802448825
32. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized
phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with
early rheumatoid arthritis. Am J Clin Nutr (2006) 84:1463–72.
33. Chen CY, Tsai CY, Lee PC, Lee SD. Long-term etanercept therapy favors
weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles
of gut hormones and leptin. Curr Pharm Des (2013) 19:1956–64. doi:10.2174/
1381612811319100014
34. Toussirot E, Mourot L, Dehecq B, Wendling D, Grandclement E, Dumoulin G.
TNFalpha blockade for inflammatory rheumatic diseases is associated with a
significant gain in android fat mass and has varying effects on adipokines: a 2-
year prospective study. Eur J Nutr (2014) 53:951–61. doi:10.1007/s00394-013-
0599-2
35. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of inflix-
imab treatment on insulin resistance in patients with rheumatoid arthritis and
ankylosing spondylitis. Ann Rheum Dis (2005) 64:765–6. doi:10.1136/ard.2004.
026534
36. Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M, Straub RH. Anti-TNF anti-
body treatment improves glucocorticoid induced insulin-like growth factor 1
(IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1
and 3. Ann Rheum Dis (2006) 65:301–5. doi:10.1136/ard.2005.040816
37. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-
Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the
anti-TNF-alpha therapy. Ann N Y Acad Sci (2010) 1193:153–9. doi:10.1111/j.
1749-6632.2009.05287.x
38. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A,
et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell
function and insulin signaling in active rheumatoid arthritis patients with high
insulin resistance. Arthritis Res Ther (2012) 14:R141. doi:10.1186/ar3874
39. Hakkinen A, Sokka T, Kotaniemi A, Hannonen P. A randomized two-year study
of the effects of dynamic strength training on muscle strength, disease activ-
ity, functional capacity, and bone mineral density in early rheumatoid arthritis.
Arthritis Rheum (2001) 44:515–22. doi:10.1002/1529-0131(200103)44:3<515:
:AID-ANR98>3.0.CO;2-5
40. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, Schoones J, Van den Ende
EC. Dynamic exercise programs (aerobic capacity and/or muscle strength
training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev
(2009):CD006853. doi:10.1002/14651858.CD006853.pub2
41. Sharif S, Thomas JM, Donley DA, Gilleland DL, Bonner DE, McCrory JL,
et al. Resistance exercise reduces skeletal muscle cachexia and improves mus-
cle function in rheumatoid arthritis. Case Report Med (2011) 2011:205691.
doi:10.1155/2011/205691
42. Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P. Efficacy of resistance
exercises in rheumatoid arthritis: meta-analysis of randomized controlled
trials. Rheumatology (Oxford) (2012) 51:519–27. doi:10.1093/rheumatology/
ker330
43. Marcora S, Lemmey A, Maddison P. Dietary treatment of rheumatoid
cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a
randomised controlled trial. Clin Nutr (2005) 24:442–54. doi:10.1016/j.clnu.
2005.01.006
44. Marcora SM, Lemmey AB, Maddison PJ. Can progressive resistance training
reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J
Rheumatol (2005) 32:1031–9.
45. Lemmey AB, Marcora SM, Chester K, Wilson S, Casanova F, Maddison
PJ. Effects of high-intensity resistance training in patients with rheumatoid
arthritis: a randomized controlled trial. Arthritis Rheum (2009) 61:1726–34.
doi:10.1002/art.24891
46. Dumortier M, Brandou F, Perez-Martin A, Fedou C, Mercier J, Brun JF. Low
intensity endurance exercise targeted for lipid oxidation improves body compo-
sition and insulin sensitivity in patients with the metabolic syndrome. Diabetes
Metab (2003) 29:509–18. doi:10.1016/S1262-3636(07)70065-4
47. Mikkelsen UR, Couppe C, Karlsen A, Grosset JF, Schjerling P, Mackey AL,
et al. Life-long endurance exercise in humans: circulating levels of inflam-
matory markers and leg muscle size. Mech Ageing Dev (2013) 134:531–40.
doi:10.1016/j.mad.2013.11.004
48. Hakkinen A, Pakarinen A, Hannonen P, Kautiainen H, Nyman K, Kraemer WJ,
et al. Effects of prolonged combined strength and endurance training on physi-
cal fitness, body composition and serum hormones in women with rheumatoid
arthritis and in healthy controls. Clin Exp Rheumatol (2005) 23:505–12.
Frontiers in Nutrition | Clinical Nutrition November 2014 | Volume 1 | Article 20 | 6
Masuko Rheumatoid cachexia revisited
49. Strasser B, Leeb G, Strehblow C, Schobersberger W, Haber P, Cauza E.
The effects of strength and endurance training in patients with
rheumatoid arthritis. Clin Rheumatol (2011) 30:623–32. doi:10.1007/s10067-
010-1584-2
50. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-
inflammatory and immunomodulating drugs. Ann Rheum Dis (2007) 66(Suppl
3):iii52–5.
51. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van
Riel PL. Modified disease activity scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal study of patients
with rheumatoid arthritis. Arthritis Rheum (1995) 38:44–8. doi:10.1002/art.
1780380107
52. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American
College of Rheumatology 1991 revised criteria for the classification of global
functional status in rheumatoid arthritis. Arthritis Rheum (1992) 35:498–502.
doi:10.1002/art.1780350502
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 September 2014; accepted: 03 November 2014; published online: 24
November 2014.
Citation: Masuko K (2014) Rheumatoid cachexia revisited: a metabolic co-morbidity
in rheumatoid arthritis. Front. Nutr. 1:20. doi: 10.3389/fnut.2014.00020
This article was submitted to Clinical Nutrition, a section of the journal Frontiers in
Nutrition.
Copyright © 2014 Masuko. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org November 2014 | Volume 1 | Article 20 | 7
